EUVIMEDEUVIMED entdecken
Crossref

Mechanisms of resistance to ceftazidime/avibactam in mutants derived in vitro from Klebsiella pneumoniae producing OXA-48-like enzymes

T Blanco-Martín, J Guzmán-Puche, M Hernández-García iD, M Muñoz-Rosa iD, C Elías-López iD, C Riazzo iD, J Torre-Cisneros, J Arca-Suárez iD, M Causse, G Bou, R Cantón iD, L Martínez-Martínez

Journal of Antimicrobial Chemotherapy · 02.12.2025 · 80 (12) · 3265-3272

DOI: 10.1093/jac/dkaf360 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 29.09.2025. Verfasst von T Blanco-Martín und 11 weiteren Autor:innen. Beteiligte Einrichtung: Unidad de Gestión Clínica de Microbiología, Hospital Universitario Reina Sofía, Córdoba, Spain. Hauptthemen laut MEDLINE: Ceftazidime, Klebsiella pneumoniae, Azabicyclo Compounds, beta-Lactamases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Instituto de Salud Carlos III, European Union, Centro de Investigación Biomédica en Red de Enfermedades Infecciosas.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To generate in vitro ceftazidime-avibactam-resistant mutants derived from Klebsiella pneumoniae producing OXA-48 or OXA-48 derivatives OXA-131 and OXA-232 carbapenemases, to define their antimicrobial susceptibility phenotype and to analyse mutations potentially involved in resistance to ceftazidime-avibactam.

Methods

Mutants were obtained by plating overnight bacterial cultures on Mueller-Hinton agar plates containing increasing concentrations of ceftazidime-avibactam (0.5/4–32/4 mg/L). MICs were determined using Sensititre™ DKMNG panels. Whole-genome sequencing of 8 parental strains and 31 mutant derivatives was performed with Illumina.

Results

All parental strains were susceptible to ceftazidime-avibactam (MIC ≤ 0.5/4–2/4 mg/L) and either susceptible or resistant to meropenem (MIC 0.5 to >16 mg/L) and imipenem (MIC ≤ 0.5 to >16 mg/L). MICs of ceftazidime-avibactam for the mutants increased up to 4 to >16 mg/L, while MICs of meropenem and imipenem for most mutants either increased up to >16 mg/L or remained unchanged. Whole-genome sequencing of the mutants identified alterations in genes coding for proteins related to AcrAB-TolC (AcrB, AcrR), PBPs (PBP2, PBP3), porins (OmpK36, EnvZ) or the stress or stringent responses (RseB, CpxA, SpoT). No mutations were detected in genes coding for OXA-48-like enzymes or other β-lactamases.

Conclusions

Ceftazidime-avibactam can select in vitro mutants of OXA-48-like carbapenemase-producing K. pneumoniae resistant to this combination and, in some cases, also to carbapenems. No mutations related to ceftazidime-avibactam resistance were found in genes coding OXA-48-like enzymes, but they were detected in genes related to active efflux, PBPs, permeability or proteins of the stress and stringent responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CeftazidimeKlebsiella pneumoniaeAzabicyclo Compoundsbeta-LactamasesAnti-Bacterial AgentsDrug Resistance, BacterialMicrobial Sensitivity TestsDrug CombinationsWhole Genome SequencingMutationHumansBacterial ProteinsKlebsiella InfectionsDrug Resistance, Multiple, Bacterial

Substanzen

CeftazidimeAzabicyclo Compoundsavibactam, ceftazidime drug combinationbeta-LactamasesDrug CombinationsAnti-Bacterial AgentsBacterial Proteinsoxacillinasecarbapenemase

Autor:innen und Institutionen

  • Unidad de Gestión Clínica de Microbiología, Hospital Universitario Reina Sofía, Córdoba, Spain.
  • Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain.
  • CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
  • Servicio de Microbiología, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.
  • Servicio de Enfermedades Infecciosas, Hospital Universitario Reina Sofía, Córdoba, Spain.
  • Departamento de Ciencias Médicas y Quirúrgicas, Universidad de Córdoba, Córdoba, Spain.

ORCID-Profile: M Hernández-García, M Muñoz-Rosa, C Elías-López, C Riazzo, J Arca-Suárez, R Cantón

Förderung

  • Instituto de Salud Carlos III
  • European Union
  • Centro de Investigación Biomédica en Red de Enfermedades Infecciosas
  • National Plan for Scientific Research, Development and Technological Innovation
  • ISCIII-General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund
  • Spanish Society of Infectious Diseases and Clinical Microbiology
  • Service of Microbiology
  • University Hospital Ramón y Cajal

Zitieren

APA

Blanco-Martín, T., Guzmán-Puche, J., Hernández-García, M., Muñoz-Rosa, M., Elías-López, C., Riazzo, C., Torre-Cisneros, J., Arca-Suárez, J., Causse, M., Bou, G., Cantón, R., & Martínez-Martínez, L. (2025). Mechanisms of resistance to ceftazidime/avibactam in mutants derived in vitro from Klebsiella pneumoniae producing OXA-48-like enzymes. Journal of Antimicrobial Chemotherapy, 80(12), 3265-3272. https://doi.org/10.1093/jac/dkaf360

Vancouver

Blanco-Martín T, Guzmán-Puche J, Hernández-García M, Muñoz-Rosa M, Elías-López C, Riazzo C, et al. Mechanisms of resistance to ceftazidime/avibactam in mutants derived in vitro from Klebsiella pneumoniae producing OXA-48-like enzymes. Journal of Antimicrobial Chemotherapy. 2025;80(12):3265-3272. doi:10.1093/jac/dkaf360

BibTeX
@article{BlancoMartn2025,
  author = {Blanco-Martín, T and Guzmán-Puche, J and Hernández-García, M and Muñoz-Rosa, M and Elías-López, C and Riazzo, C and Torre-Cisneros, J and Arca-Suárez, J and Causse, M and Bou, G and Cantón, R and Martínez-Martínez, L},
  title = {Mechanisms of resistance to ceftazidime/avibactam in mutants derived in vitro from Klebsiella pneumoniae producing OXA-48-like enzymes},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  volume = {80},
  number = {12},
  pages = {3265--3272},
  doi = {10.1093/jac/dkaf360}
}
Kostenlos starten →